On 2 September, an op-ed published by IOL argued that wastewater surveillance should be folded into routine public-health monitoring of antimicrobial resistance, rather than left as a patchwork of short research projects. The submission was written by Dr. Jose L. Balcazar, senior microbiologist at the Catalan Institute for Water Research (ICRA-CERCA) in Spain, and it frames municipal sewer systems as a population-scale early warning tool that is already proven but under-deployed (IOL).
Key takeaways
- Dr. Jose L. Balcazar of ICRA-CERCA submitted the op-ed to IOL on 2 September calling for wastewater monitoring of antimicrobial resistance to be treated as public-health infrastructure, not a research side project (IOL).
- Antimicrobial resistance is already linked to an estimated 1.3 million deaths a year, according to the op-ed (IOL).
- The author says wastewater-based monitoring proved its value during the COVID-19 pandemic and can deliver population-level, anonymised, relatively low-cost health intelligence (IOL).
- The piece flags fragmented methodologies and inconsistent data integration as the main barriers to scaling up AMR surveillance in sewage (IOL).
- The author calls for investment in standardised methods, better data sharing and stronger ties between scientists, policymakers and infrastructure providers (IOL).
What happened
Balcazar's submission positions municipal sewage as a near-real-time mirror of community-level antibiotic use and resistance, because "every day, human activity leaves biological traces such as bacteria, viruses, chemical residues and genetic material that flow into sewer systems" (IOL). He contrasts that capability with the disease burden, noting that "antimicrobial resistance is already responsible for an estimated 1.3 million deaths each year" (IOL).
The op-ed acknowledges that AMR surveillance is harder than pandemic pathogen tracking because it requires monitoring "a dynamic landscape of resistance genes, microbial communities and environmental pressures" rather than a single virus, and that "today, wastewater monitoring for antimicrobial resistance remains fragmented and is often confined to short-term research projects" (IOL). The author frames the bottleneck as implementation, not science, and argues the next step is a "shift from isolated research efforts to integrated public health strategies" backed by standardised methods and shared data (IOL).
Specification read
No plant capacity, pollutant concentration or population-equivalent figure is given in the source, so any scaling here is a class range, not a reported number (general industry range, not from the sources). A municipal wastewater treatment plant serving a mid-sized catchment of roughly 50,000 to 500,000 population equivalents typically handles 20,000 to 200,000 m³/day, with raw BOD in the 150 to 400 mg/L range and COD roughly 1.5 to 2.5 times BOD, so a routine composite sampler at the headworks or inlet works can already feed a 24-hour AMR monitoring programme without altering the hydraulic train.
This event does not sit at a single unit operation; it overlays the existing treatment train, which in a Class II/III municipal plant runs screening and grit removal, primary clarification, biological treatment (commonly MBR, A2O, MBBR, SBR or UASB depending on influent strength and footprint), followed by tertiary filtration and disinfection (UV or chlorination) before discharge or reuse. The sampling point that matters for an AMR programme is typically the inlet works or the biological reactor, because resistance-gene signal and antibiotic-residue load are highest there; secondary clarification and disinfection affect what is measured but are not the primary location for surveillance sampling.
If your plant looks like a municipal or mixed-industrial site in the 20,000 to 200,000 m³/day range, with BOD around 200 to 400 mg/L and tightening effluent-quality or reuse-compliance pressure, the practical question this op-ed raises is whether your SCADA and laboratory information system can export composite-sampler metadata in a format a regional or national AMR dashboard will accept, and whether your biosolids-handling line is reporting residue data alongside flow. Plants that already serve adjacent pharmaceutical or hospital catchments should look at this as a pharma-sector data integration issue as well as a wastewater one (IOL).
FAQ
What does the op-ed actually propose for wastewater utilities? It calls for standardised sampling methods, shared data formats and routine integration of sewer monitoring into public-health surveillance, with investment from infrastructure providers alongside scientists and policymakers (IOL).
Is there a defined treatment-stage upgrade this implies? No new unit process is specified. Implementation hinges on the existing inlet-works sampler, the biological reactor and the data export layer; secondary and tertiary stages are affected only in how their performance data are reported. This section is engineering interpretation, not a reported fact (general industry range, not from the sources).
What is the lead time to add an AMR monitoring programme to a working plant? The op-ed does not give a timeline. For a mid-sized municipal plant, installing a refrigerated composite autosampler, a 24-hour flow-paced programme and a sequencing/genomics subcontract is typically a 3 to 6 month project, with parallel data-format work for national dashboards (general industry range, not from the sources).
Who pays for this in the model the author describes? The submission asks for "investment in standardised methods, improved data sharing, and stronger collaboration between scientists, policymakers and infrastructure providers" but does not name a funding mechanism or cost figure (IOL).
